​LONDON—GW Pharmaceuticals PLC said its marijuana-derived drug for children with severe epilepsy significantly cut the number of seizures they suffered during a Phase III trial, possibly paving the way for the first U.S. approval of a drug of its kind.

Shares in the company more than doubled in trading Monday, rising 140% to close at 519 pence ($7.46) in London.

The...